Uncategorized
Affibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection
Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to showcase the inflammation drug’s potential to prospective partners.